CD16 (FcγRIII) is a low affinity Fc receptor that binds to IgG antibodies. Two forms of the receptor, CD16A (FcγRIIIa) and CD16B (FcγRIIIb) are present in natural killer cells, neutrophils, monocytes and activated macrophages. Antibody-dependent cell-mediated cytotoxicity (ADCC), cytokine release and microbe killing can be induced upon binding with CD16.

Sconocchia, et al. demonstrated in a recent study that colorectal carcinoma patients with high CD16+ cell infiltration was associated with improved overall survival after adjusting for known prognostic factors and this association was independent from CD8+ lymphocyte infiltration and presence of metastases.